CD19 and acute lymphoblastic leukemia: One representative T-BsAb is Blinatumomab, a bi-specific T cell engager (BiTE) targeting CD19 and CD3 that was approved by FDA in 2014 for the treatment of Acute Lymphoblastic Leukemia (ALL).